EZH2 and cancer: As the core component of PRC2, EZH2 has been proven to have carcinogenic effects in cancer, but current EZH2 inhibitors are not effective in inhibiting the oncogenic activity of EZH2 [129,130]; thus, EZH2-based PROTACs were designed to degrade PRC2 complexes.